JP2023036863A5 - - Google Patents

Download PDF

Info

Publication number
JP2023036863A5
JP2023036863A5 JP2022209238A JP2022209238A JP2023036863A5 JP 2023036863 A5 JP2023036863 A5 JP 2023036863A5 JP 2022209238 A JP2022209238 A JP 2022209238A JP 2022209238 A JP2022209238 A JP 2022209238A JP 2023036863 A5 JP2023036863 A5 JP 2023036863A5
Authority
JP
Japan
Prior art keywords
lamp
seq
dendritic cell
amino acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022209238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023036863A (ja
JP7407902B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/030725 external-priority patent/WO2018204534A1/en
Application filed filed Critical
Publication of JP2023036863A publication Critical patent/JP2023036863A/ja
Publication of JP2023036863A5 publication Critical patent/JP2023036863A5/ja
Priority to JP2023213451A priority Critical patent/JP7657282B2/ja
Application granted granted Critical
Publication of JP7407902B2 publication Critical patent/JP7407902B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022209238A 2017-05-02 2022-12-27 癌抗原を含む改善されたlamp構築物 Active JP7407902B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023213451A JP7657282B2 (ja) 2017-05-02 2023-12-19 癌抗原を含む改善されたlamp構築物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762500053P 2017-05-02 2017-05-02
US62/500,053 2017-05-02
US201762561760P 2017-09-22 2017-09-22
US62/561,760 2017-09-22
PCT/US2018/030725 WO2018204534A1 (en) 2017-05-02 2018-05-02 Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
JP2019560156A JP7222915B2 (ja) 2017-05-02 2018-05-02 癌抗原を含む改善されたlamp構築物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019560156A Division JP7222915B2 (ja) 2017-05-02 2018-05-02 癌抗原を含む改善されたlamp構築物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023213451A Division JP7657282B2 (ja) 2017-05-02 2023-12-19 癌抗原を含む改善されたlamp構築物

Publications (3)

Publication Number Publication Date
JP2023036863A JP2023036863A (ja) 2023-03-14
JP2023036863A5 true JP2023036863A5 (https=) 2023-05-15
JP7407902B2 JP7407902B2 (ja) 2024-01-04

Family

ID=62528827

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019560156A Active JP7222915B2 (ja) 2017-05-02 2018-05-02 癌抗原を含む改善されたlamp構築物
JP2022209238A Active JP7407902B2 (ja) 2017-05-02 2022-12-27 癌抗原を含む改善されたlamp構築物
JP2023213451A Active JP7657282B2 (ja) 2017-05-02 2023-12-19 癌抗原を含む改善されたlamp構築物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019560156A Active JP7222915B2 (ja) 2017-05-02 2018-05-02 癌抗原を含む改善されたlamp構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023213451A Active JP7657282B2 (ja) 2017-05-02 2023-12-19 癌抗原を含む改善されたlamp構築物

Country Status (10)

Country Link
US (2) US12358962B2 (https=)
EP (1) EP3618854A1 (https=)
JP (3) JP7222915B2 (https=)
KR (2) KR20200016224A (https=)
CN (1) CN110913892A (https=)
AU (1) AU2018263923B9 (https=)
BR (1) BR112019023014A2 (https=)
CA (1) CA3061950A1 (https=)
IL (2) IL297073B2 (https=)
WO (1) WO2018204534A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12398195B2 (en) * 2018-05-15 2025-08-26 Immunomic Therapeutics, Inc. Lamp constructs comprising allergens
EP4045528A1 (en) * 2019-10-18 2022-08-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
TWI828126B (zh) * 2021-04-27 2024-01-01 中央研究院 用以治療高三酸甘油脂血症或其相關疾病的方法
US20250352639A1 (en) 2022-04-10 2025-11-20 Immunomic Therapeutics, Inc. Bicistronic LAMP Constructs Comprising Immune Response Enhancing Genes and Methods of Use Thereof

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237115A (en) 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4397844A (en) 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2026340B (en) 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
US4681762A (en) 1979-05-23 1987-07-21 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4593002A (en) 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4592002A (en) 1983-12-13 1986-05-27 Honeywell Inc. Method of digital temperature compensation and a digital data handling system utilizing the same
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
IE921342A1 (en) 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5661133B1 (en) 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
GB9213033D0 (en) 1992-06-19 1992-08-05 British Telecomm Method of controlling a telecommunications network
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
FI955320A7 (fi) 1994-03-07 1995-11-24 Univ Michigan Bioaktiivisia ja/tai kohdennettuja dendriimikonjugaatteja
WO1995028494A1 (en) 1994-04-15 1995-10-26 Targeted Genetics Corporation Gene delivery fusion proteins
FR2719316B1 (fr) 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
AU2946295A (en) 1994-06-27 1996-01-19 Johns Hopkins University, The Targeted gene delivery system
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1323346B1 (en) 1995-01-17 2006-06-28 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
WO1997035996A1 (en) 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
EP0944717A1 (fr) 1996-07-01 1999-09-29 Aventis Pharma S.A. Procede de production d'adenovirus recombinants
EP0920339A2 (en) 1996-07-09 1999-06-09 The Johns Hopkins University Gene delivery system
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
ATE477320T1 (de) 1996-12-13 2010-08-15 Schering Corp Methoden zur virus-reinigung
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2760193B1 (fr) 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
FR2763958A1 (fr) 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
AU749032B2 (en) 1997-06-13 2002-06-20 Johns Hopkins University, The Therapeutic nanospheres
CA2242035C (en) 1997-07-01 2004-11-23 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
ES2210081T3 (es) 1998-07-07 2004-07-01 Transgene S.A. Utilizacion de los marcos de lectura de la region e4 para la mejora de la expresion de genes.
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6511832B1 (en) 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
WO2001080897A2 (en) 2000-04-21 2001-11-01 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
DK1385538T3 (da) 2001-04-05 2013-04-29 Univ Johns Hopkins Kimære vacciner omfattende det lumenale domæne fra LAMP-1 eller LAMP-2
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
US20070269457A1 (en) 2006-05-16 2007-11-22 The Buck Institute For Age Research Immunotherapeutic compositions and methods
US9085638B2 (en) * 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
CN107617110A (zh) 2009-08-26 2018-01-23 西莱克塔生物科技公司 诱导t细胞辅助的组合物
WO2011046996A2 (en) 2009-10-13 2011-04-21 The Johns Hopkins University Consensus sequence for influenza a virus
BR112013026199A2 (pt) * 2011-04-15 2017-11-07 Compugen Ltd polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo
US20160185831A1 (en) 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
EP3808361A1 (en) * 2012-06-15 2021-04-21 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
US20170304432A1 (en) 2014-06-23 2017-10-26 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
KR102637960B1 (ko) * 2017-04-22 2024-02-21 이뮤노믹 쎄라퓨틱스, 인크. 개선된 lamp 구축물

Similar Documents

Publication Publication Date Title
JP2023036863A5 (https=)
JP2023015342A5 (https=)
JP2015500811A5 (https=)
JP2021524275A5 (https=)
JP2021511041A5 (https=)
JP2019522490A5 (https=)
JP2021535733A5 (https=)
WO2015105926A1 (en) Polynucleotides for the in vivo production of antibodies
RU2011141522A (ru) Антиангиогенные слитые белки
RU2009126723A (ru) Антитела к ox40l
JP2012507994A (ja) Hla−gタンパク質及びその薬学的使用
JP2006523711A5 (https=)
JP2019524100A5 (https=)
FR2920429A1 (fr) Procede de purification du facteur viii et du facteur von willebrand
JP2019530441A5 (https=)
WO2020156221A1 (zh) 人源化抗Aβ单克隆抗体及其应用
RU2015116509A (ru) Способы и композиции для лечения рассеянного склероза и связанных с ним заболеваний
JP2020535811A5 (https=)
JP2021525067A5 (https=)
CN115697372A (zh) 具有间充质干细胞的动员活性的肽
CN105924515A (zh) 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用
WO2020156220A1 (zh) 人源化抗Aβ单克隆抗体及其应用
TW200526282A (en) Extracorporeal photopheresis in combination with anti-TNF treatment
EP4204000A1 (en) Modified polypeptides with improved properties
WO2025081189A1 (en) Methods and compositions for lipid nanoparticle (lnp) mediated delivery of mrna encoded synthetic antigens for universal tumor targeting by car t cells